Descripción del proyecto
Un páncreas automatizado artificial para el tratamiento de la diabetes de tipo 1
La diabetes de tipo 1 (DM1) está relacionada con la falta de células productoras de insulina en el páncreas y suele diagnosticarse en niños y adultos jóvenes. A lo largo de su vida, los pacientes con DM1 necesitan insulina exógena. El proyecto financiado con fondos europeos FORGETDIABETES presenta un enfoque radicalmente nuevo del tratamiento de la DM1 con el desarrollo de un páncreas biónico automatizado invisible, totalmente implantable e optimizado inmunológicamente. El páncreas biónico invisible permitirá administrar insulina intraperitoneal para un control glucémico óptimo. El equipo del proyecto está formado por expertos en micro y nanomecatrónica, biomateriales, endocrinología, cirugía y ciencias conductuales. El páncreas biónico invisible de larga duración se basará en un sistema de detección de glucosa natural y de administración de insulina controlado mediante algoritmos adaptativos con capacidades avanzadas de autodiagnóstico.
Objetivo
FORGETDIABETES introduces a radically new approach to Type 1 Diabetes (T1D) treatment, by developing an immuno-optimized, fully-implantable, fully-automated, Bionic Invisible Pancreas (BIP). BIP targets physiological intraperitoneal hormone delivery, enabling an optimal glycemic control. T1D patient number is rising, projected at 63-94 million in 2045. T1D patients require exogenous insulin, resulting in an exorbitant number of actions: 100.000-500.000 in one patient’s life. BIP will free T1D subjects from therapeutic actions and from related psychological burden. BIP will become a life-condition (like wearing glasses), allowing T1D patients to live just as everybody else. An interdisciplinary team with top experts in micro-nano mechatronics, control engineering, biomaterials, endocrinology, surgery and behavioural sciences has been assembled to develop what was regarded as impossible for decades: a long-lasting system relying on a physiological glucose sensing and hormone delivery, orchestrated by personalized adaptive algorithms with advanced self-diagnostic capabilities. Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of painful and awkward daily measurement and treatment actions.
Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. In this project, the key technologies enabling BIP will be developed. Furthermore, extensive in vivo preclinical experiments along with massive in silico testing will establish the proof-of-principle, paving the way to the ambitious first-in-human inpatient trial of BIP. This paradigm will revolutionize diabetes treatment and stimulate an innovation ecosystem including research bodies, SMEs, patient organizations, diabetes societies and clinicians. By investing in efforts like FORGETDIABETES, Europe will stand at the forefront of technological innovations for T1D treatment.
Ámbito científico
- medical and health sciencesclinical medicinesurgery
- medical and health sciencesclinical medicineendocrinologydiabetes
- engineering and technologymechanical engineeringmechatronics
- engineering and technologyindustrial biotechnologybiomaterials
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringcontrol engineering
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-EIC-FETPROACT-2019
Régimen de financiación
RIA - Research and Innovation actionCoordinador
35122 Padova
Italia